Association of single and serial measures of serum phosphorus with adverse outcomes in patients on peritoneal dialysis: results from the international PDOPPS

Author:

Lopes Marcelo Barreto12,Karaboyas Angelo12,Zhao Junhui12,Johnson David W345,Kanjanabuch Talerngsak6,Wilkie Martin7,Nitta Kosaku8,Kawanishi Hideki9,Perl Jeffrey10,Pisoni Ronald L12,Johnson David,Perl Jeffrey,Sanabria Mauricio,Kawanishi Hideki,Kim Yong-Lim,Kanjanabuch Talerngsak,Davies Simon,Pisoni Ronald,Robinson Bruce,Shen Jenny,

Affiliation:

1. Arbor Research Collaborative for , Ann Arbor , MI, USA

2. Health , Ann Arbor , MI, USA

3. Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia

4. Department of Nephrology, Princess Alexandra Hospital , Brisbane , Australia

5. Translational Research Institute , Brisbane , Australia

6. Center of Excellence in Kidney Metabolic Disorders and Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand

7. Sheffield Kidney Institute, Sheffield Teaching Hospital NHS Foundation Trust , Sheffield , UK

8. Department of Nephrology, Tokyo Women's Medical University , Tokyo , Japan

9. Tsuchiya General Hospital , Hiroshima , Japan

10. St Michael's Hospital, University of Toronto , Toronto, ON, Canada

Abstract

ABSTRACT Background While high serum phosphorus levels have been related to adverse outcomes in hemodialysis patients, further investigation is warranted in persons receiving peritoneal dialysis (PD). Methods Longitudinal data (2014–17) from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS), a prospective cohort study, were used to examine associations of serum phosphorus with all-cause mortality and major adverse cardiovascular events via Cox regression adjusted for confounders. Serum phosphorus levels were parameterized by four methods: (i) baseline serum phosphorus; (ii) mean 6-month serum phosphorus; (iii) number of months with serum phosphorus >4.5 mg/dL; and (iv) mean area-under-the-curve of 6-month serum phosphorus control. Results The study included 5847 PD patients from seven countries; 9% of patients had baseline serum phosphorus <3.5 mg/dL, 24% had serum phosphorus ≥3.5 to ≤4.5 mg/dL, 30% had serum phosphorus >4.5 to <5.5 mg/dL, 20% had serum phosphorus ≥5.5 to <6.5 mg/dL, and 17% had serum phosphorus ≥6.5 mg/dL. Compared with patients with baseline serum phosphorus ≥3.5 to ≤4.5 mg/dL, the adjusted all-cause mortality hazard ratio (HR) was 1.19 (0.92,1.53) for patients with baseline serum phosphorus ≥5.5 to <6.5 mg/dL and HR was 1.53 (1.14,2.05) for serum phosphorus ≥6.5 mg/dL. Associations between serum phosphorus measurements over 6 months and clinical outcomes were even stronger than for a single measurement. Conclusions Serum phosphorus >5.5 mg/dL was highly prevalent (37%) in PD patients, and higher serum phosphorus levels were a strong predictor of morbidity and death, particularly when considering serial phosphorus measurements. This highlights the need for improved treatment strategies in this population. Serial serum phosphorus measurements should be considered when assessing patients’ risks of adverse outcomes.

Funder

Akebia Therapeutics, Inc.

Baxter Healthcare Corporation

Fresenius Medical Care

NHMRC

AstraZeneca

Bayer

Awak

Ono

BI & Lilly

Amgen

Chulalongkorn University

National Research Council of Thailand

Kidney Foundation of Thailand

Faculty of Medicine

VISTERRA

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3